UBS Maintains AbbVie(ABBV.US) With Hold Rating, Cuts Target Price to $181

瑞士银行维持艾伯维公司(ABBV.US)持有评级，下调目标价至181美元

moomoo资讯 · 2024/11/13 03:32 · 评级/大行评级

UBS analyst Trung Huynh maintains $AbbVie (ABBV.US)$ with a hold rating, and adjusts the target price from $195 to $181.

According to TipRanks data, the analyst has a success rate of 72.7% and a total average return of 14.5% over the past year.

AnalystRecentRatingAutoNews_206654_20241112_5b6b1e5b433f0786a470bcc13c0a7790ca86c3b1_1731493927873743_mm_en

Furthermore, according to the comprehensive report, the opinions of $AbbVie (ABBV.US)$'s main analysts recently are as follows:

The revision of expectations for AbbVie followed an unexpected update on their Phase 2 study of emraclidine. After removing emraclidine from the projection and adjusting the estimates for Cobenfy for another company, the total anticipated revenue for 2033 has increased by 7%. This alteration, however, is not expected to significantly affect the overall revenue or earnings per share growth trajectory for either company.
The pivotal Phase 2 data for AbbVie's emraclidine did not meet expectations, failing to show a statistically significant change from baseline in the Positive and Negative Symptom Scale total score in studies for schizophrenia. This was a key factor in AbbVie's acquisition of Cerevel, with emraclidine projected to generate substantial sales and compete against Coben. The analyst has since removed emraclidine from their financial model.
The firm acknowledges that the outcomes of the EMPOWER 1 and 2 Emraclidine Phase 2 studies in Schizophrenia, where placebo outperformed both active arms in both trials, have led to the realization that the central value proposition of the significant acquisition is effectively negated.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

瑞士银行分析师Trung Huynh维持$艾伯维公司 (ABBV.US)$持有评级，并将目标价从195美元下调至181美元。

根据TipRanks数据显示，该分析师近一年总胜率为72.7%，总平均回报率为14.5%。

AnalystRecentRatingAutoNews_206654_20241112_5b6b1e5b433f0786a470bcc13c0a7790ca86c3b1_1731493927873743_mm_sc

此外，综合报道，$艾伯维公司 (ABBV.US)$近期主要分析师观点如下：

对AbbVie的预期调整是在其对emraclidine的2期研究出人意料地更新之后进行的。在将emraclidine从预测中删除并调整了另一家公司的Cobenfy的估计值后，2033年的预期总收入增长了7％。但是，预计这种变化不会对两家公司的整体收入或每股收益的增长轨迹产生重大影响。
AbbVie的emraclidine的关键2期数据没有达到预期，未能显示精神分裂症研究中阳性和阴性症状量表总分与基线相比有统计学上的显著变化。这是艾伯维收购Cerevel的关键因素，预计emraclidine将带来可观的销售额并与Coben竞争。此后，该分析师已将emraclidine从其财务模型中删除。
该公司承认，针对精神分裂症的EMPOWER 1和2 Emraclidine二期研究的结果使人们认识到，此次重大收购的核心价值主张实际上被否定了，安慰剂在这两项试验中的表现都超过了两个活性组。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

UBS Maintains AbbVie(ABBV.US) With Hold Rating, Cuts Target Price to $181

UBS Maintains AbbVie(ABBV.US) With Hold Rating, Cuts Target Price to $181

风险及免责提示

声明